From a 600,000-veteran addiction study to fewer daily steps on smartwatches, scientists including Naveed Sattar weigh in on what GLP-1s do beyond appetite.
Recap by typeshit. Full story at BBC Science Focus Magazine.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
NPR counted over 1,000 FDA reports of optic neuropathy tied to GLP-1s since 2024. Novo Nordisk calls the claims meritless and Lilly says it will fight them.
A new survey points to a hard money choice for some Americans: paying for Ozempic or putting that cash toward retirement. NewsNation has the numbers.
Loading…